Metabolic alterations in Parkinson’s disease astrocytes
Tuuli-Maria Sonninen, Riikka H. Hämäläinen, Marja Koskuvi, Minna Oksanen, Anastasia Shakirzyanova, Sara Wojciechowski, Katja A. Puttonen, Nikolay Naumenko, Gundars Goldsteins, Nihay Laham-Karam, Marko Lehtonen, Pasi Tavi, Jari Koıstınaho, Šárka Lehtonen
Abstract
Abstract In Parkinson`s disease (PD), the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta is associated with Lewy bodies arising from the accumulation of alpha-synuclein protein which leads ultimately to movement impairment. While PD has been considered a disease of the DA neurons, a glial contribution, in particular that of astrocytes, in PD pathogenesis is starting to be uncovered. Here, we report findings from astrocytes derived from induced pluripotent stem cells of LRRK2 G2019S mutant patients, with one patient also carrying a GBA N370S mutation, as well as healthy individuals. The PD patient astrocytes manifest the hallmarks of the disease pathology including increased expression of alpha-synuclein. This has detrimental consequences, resulting in altered metabolism, disturbed Ca 2+ homeostasis and increased release of cytokines upon inflammatory stimulation. Furthermore, PD astroglial cells manifest increased levels of polyamines and polyamine precursors while lysophosphatidylethanolamine levels are decreased, both of these changes have been reported also in PD brain. Collectively, these data reveal an important role for astrocytes in PD pathology and highlight the potential of iPSC-derived cells in disease modeling and drug discovery.